Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France — DIAPAZON  

Type 2 Diabetes Mellitus (T2D) Clinical Trial

Official title: Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France

Status Completed

Clinical Trial Summary

The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety

Clinical Trial Description

Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period, Retrospective follow by Prospective. ;

Study Design

Observational Model: Cohort

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type 2 Diabetes Mellitus (T2D)

• NCT number: NCT01552005
• Study type: Observational
• Source: AstraZeneca
• Status: Completed
• Phase: N/A
• Start date: May 2012
• Completion date: June 2015